RET and non-small cell lung carcinoma: The development of selective inhibitors against these targets (e.g., larotrectinib for NTRK and selpercatinib for RET) has shown unprecedented efficacy in clinical trials, offering new hope for previously untreatable NSCLC subgroups (Cocco et al., 2018).